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EVERE illnesses, trauma, anesthesia, and sur-
gery are accompanied by activation of the hypo-
thalamic–pituitary–adrenal axis, as demonstrat-
ed by increased serum corticotropin and cortisol
concentrations.
 
1-7
 
 This activation is an essential com-
ponent of the general adaptation to stress and con-
tributes to the maintenance of homeostasis.
 
8
 
 The
efficacy of replacement doses or high doses of cor-
ticosteroids in patients with severe illness, especial-
ly those with multiorgan-system diseases, is uncer-
tain.
 
9-12
 
 The uncertainty is even greater in patients
who are already taking corticosteroids. Standard ther-
apy for the latter patients consists of the administra-
tion of high doses of corticosteroids during any severe
illness and perioperatively. We review here the value
of corticosteroid administration during severe illness
in patients with normal hypothalamic–pituitary–adre-
nal function and in patients receiving corticosteroid
treatment or replacement therapy before the illness.
 
EFFECT OF CORTICOSTEROIDS 
ON CIRCULATORY ASPECTS 
OF THE STRESS RESPONSE
 
Cortisol has a vital supportive role in the main-
tenance of vascular tone, endothelial integrity, vas-
cular permeability, and the distribution of total
body water within the vascular compartment.
 
13-15
 
 It
also potentiates the vasoconstrictor actions of cate-
cholamines.
 
13,14
 
 Adrenalectomy predisposes animals
to hypovolemic and laparotomy-induced circulatory
shock,
 
16,17
 
 which can be prevented by replacement
doses of corticosteroids.
 
18
 
In humans, chronic adrenal deficiency is charac-
terized by decreased systemic vascular resistance and
S
 
decreased cardiac contractility. However, a variety of
hemodynamic abnormalities have been described dur-
ing acute adrenal insufficiency. They include hypo-
volemic shock (decreased preload, depressed myo-
cardial contractility, and increased systemic vascular
resistance)
 
19,20
 
 and hyperdynamic shock (high cardi-
ac output and decreased systemic vascular resistance
similar to those in septic shock).
 
20-24
 
 These different
hemodynamic findings may reflect the fact that some
patients had already received some volume replace-
ment before cardiovascular function was studied or
that their mineralocorticoid secretion varied depend-
ing on whether they had primary or secondary ad-
renal insufficiency. One important conclusion is that
hypotension in patients with adrenal insufficiency
may mimic either hypovolemic or septic shock, a con-
clusion that emphasizes the need to include adrenal
insufficiency in the differential diagnosis of both.
 
20
 
THE NORMAL RESPONSE OF THE 
HYPOTHALAMIC–PITUITARY–ADRENAL 
AXIS TO CRITICAL ILLNESS AND THE 
CONCEPT OF RELATIVE ADRENAL 
INSUFFICIENCY
 
Pain, fever, and hypovolemia all result in a sustained
increase in corticotropin and cortisol secretion.
 
8,25,26
 
During surgical procedures such as laparotomy, se-
rum corticotropin and cortisol concentrations rise
rapidly but usually return to base-line values within
24 to 48 hours
 
27,28
 
 (Fig. 1A). The magnitude of the
postoperative increase in serum cortisol concentra-
tions is positively correlated with the extent of sur-
gery.
 
29,31
 
 As compared with the concentrations be-
fore surgery, mean serum cortisol concentrations
measured for 24 hours beginning two days after sur-
gery were increased by 84 percent after laparotomy,
but by only 36 percent after less extensive proce-
dures such as operations on the joints, breast, or
neck (P
 

 
0.005).
 
32
 
 After operation, there is initial-
ly no circadian variation in serum cortisol concen-
trations (Fig. 1A). During severe illness, serum cor-
tisol concentrations tend to be even higher (Fig.
1B).
 
30,32-34
 
 The values are highest in patients with the
highest illness-severity scores
 
3,5,7,30,32-35
 
 and in those
with the highest mortality,
 
5
 
 and the values are very
high (30 to 260 
 
m
 
g per deciliter [828 to 7173 nmol
per liter]) shortly before death.
 
36
 
Adrenal function in severely ill patients is often eval-
uated by a corticotropin-stimulation test, in which
serum cortisol is measured at base line and 30 to
60 minutes after the intravenous administration of
250 
 
m
 
g of cosyntropin. The interpretation of the re-
sponses is difficult in seriously ill patients, however. Se-
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rum cortisol concentrations that are regarded as nor-
mal in normal subjects may be inappropriately low in
patients who are severely ill, suggesting the existence
of relative adrenal insufficiency. For example, a cortisol
concentration of less than 10 
 
m
 
g per deciliter (276
nmol per liter) in a random serum sample has been
proposed as abnormal during acute illness
 
37
 
 and, con-
versely, serum cortisol concentrations above 18 
 
m
 
g per
deciliter (497 nmol per liter) after corticotropin stim-
ulation as indicating adequate adrenal reserve. 
Several patterns of response in critically ill patients
can be recognized. In most patients, serum cortisol
concentrations increase to levels above 18 
 
m
 
g per dec-
iliter after the administration of corticotropin,
 
38-40
 
 but
in those with high base-line serum cortisol concentra-
tions, the increment after corticotropin administration
may be small, a finding that might have a predictive
value with regard to mortality.
 
5
 
 Among 32 patients
with septic shock, all but 1 of whom had basal serum
cortisol concentrations above 11 
 
m
 
g per deciliter (303
nmol per liter), all 13 who had a poor response to cor-
ticotropin (increase in serum cortisol, less than 9 
 
m
 
g
per deciliter [248 nmol per liter]) died. In contrast,
only 6 of the 19 patients who had an increase in serum
cortisol of more than 9 
 
m
 
g per deciliter died.
 
41
 
 In an-
other study, 5 of 26 patients with sepsis had subnor-
mal responses; only 1 of the 5 patients survived, and
this patient was treated with corticosteroids.
 
25
 
 On the
other hand, the failure of the rapid corticotropin test
to reveal corticotropin deficiency demonstrable by in-
sulin tolerance
 
42,43
 
 or metyrapone testing
 
44,45
 
 means
that it cannot be fully relied on, especially in patients
with hypothalamic or pituitary disease.
 
46
 
The relative lack of a serum cortisol response to
 
Figure 1.
 
 Serum Cortisol Concentrations during Surgery and
Acute Illness.
Panel A shows the serum cortisol concentrations in a 70-year-
old patient who underwent total gastrectomy. The circadian
rhythm of serum cortisol on the day before surgery was nor-
mal. Serum cortisol concentrations increased markedly during
and after surgery (day 0), remaining high for more than 72
hours with no apparent circadian rhythm until day 7. M de-
notes midnight. Adapted from Naito et al.
 
29
 
 with the permis-
sion of the publisher.
Panel B shows the mean (
 

 
SD) serum cortisol concentrations
on admission (day 0), at eight-hour intervals on days 1 and 2,
and once daily on days 3 to 8 in 18 consecutive patients with
severe sepsis and 12 patients who underwent surgery for mul-
tiple trauma. The serum cortisol concentrations remained ele-
vated for more than a week. Adapted from Vermes et al.
 
30
 
 with
the permission of the publisher. To convert values for cortisol
to nanomoles per liter, multiply by 27.6.
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corticotropin in some critically ill patients may be due
to the fact that the normal hypothalamic–pituitary–
adrenal axis is already maximally stimulated, but it
may also be due to interference with the corticoster-
oid-synthesizing capacity of the adrenal cortex (for
example, by adrenal hemorrhage, adrenal metastases,
or drugs; see below and Table 1). Support for a con-
tributory role of limited adrenocortical reserve in the
deterioration of critically ill patients comes from a
study showing that, of 133 consecutive patients in an
intensive care unit whose morning serum cortisol
concentrations progressively fell to less than 11.8 
 
m
 
g
per deciliter (326 nmol per liter), 27 percent died.
 
48
 
In recent years there have been reports of a num-
ber of critically ill patients with relative adrenal in-
sufficiency.
 
49,50
 
 Virtually all these patients had com-
plicated multiorgan disease, high cardiac output, low
peripheral vascular resistance, shock, and normal se-
rum cortisol concentrations, findings that rule out
primary adrenal insufficiency. In these patients, ad-
ministration of hydrocortisone (100 to 300 mg per
24 hours) diminished or eliminated the requirement
for vasopressor drugs, supporting the concept of oc-
cult relative adrenal insufficiency.
 
10,11
 
Evidence of the important role of intact hypotha-
lamic–pituitary–adrenal function in the survival of
critically ill patients with multiple trauma and the role
of occult relative adrenal insufficiency comes from the
intensive care unit of the University Hospital of Glas-
gow, Scotland.
 
51
 
 Between 1969 and 1980, the mor-
tality rate among patients with multiple injuries var-
ied between 22 and 29 percent. In 1981 and 1982,
mortality rose to 44 percent, despite the absence of
change in the injury-severity score of the patients at
the time of admission. This increase in mortality co-
incided with the introduction of a short-acting hyp-
notic drug, etomidate, given to optimize respiratory
assistance. This drug was subsequently found to be a
selective inhibitor of adrenal 11
 
b
 
-hydroxylase, the en-
zyme that converts deoxycortisol to cortisol.
 
52
 
 
As shown in Figure 2, administration of etomidate
during an elective short surgical procedure was ac-
companied by a subnormal increase in serum cortisol
concentrations, despite an increase in corticotropin
and deoxycortisol secretion. The clinical outcome of
the minor surgical procedure was not altered in these
patients. However, in patients with multiple injuries
(including those with hypovolemia, infections, and
organ failure), etomidate-induced partial adrenocorti-
cal insufficiency seemed to be the additional factor
that changed the course of the illness, nearly doubling
mortality.
 
51,53
 
 These findings indicate that even slight
impairment of the adrenal response during severe ill-
ness can be lethal, and they support the concept that
the apparently poor serum cortisol responses to cor-
ticotropin and the decline in morning serum cortisol
concentrations in these patients may be causes, rather
than consequences, of the severe illness.
The incidence of acute (total) adrenal insufficien-
cy after routine surgery is low, ranging from 0.01 to
0.7 percent in more than 70,000 patients.
 
54-56
 
 Total
adrenal insufficiency is also rare in severely ill pa-
tients, occurring in 2 to 3 percent of patients.
 
3,5,57
 
However, the notion of total adrenal insufficiency
has been gradually replaced by the concept of occult
or relative adrenal insufficiency, caused by preexist-
ing disease, concomitant factors, or complications
that only partially reduce the adrenocortical capacity
to produce cortisol (Table 1). This relative adrenal
insufficiency might contribute to a fatal outcome,
especially in patients with multiorgan failure.
 
25,58
 
Symptoms and signs that might raise suspicion of
the existence of relative adrenal insufficiency are
shown in Table 2. Inappropriately low serum corti-
sol concentrations or impaired serum cortisol re-
sponses to corticotropin also suggest the presence of
relative adrenal insufficiency. It is important to rec-
ognize this condition, because therapy with cortico-
steroids can improve the clinical condition of these
patients, making their outcome dependent only on
the underlying disease.
In conclusion, the practical use of the corticotro-
pin test in severely ill patients is at present limited to
the diagnosis of total adrenal insufficiency, and in
exceptional cases the diagnosis of secondary adrenal
insufficiency is missed. No strict biochemical criteria
for relative adrenal insufficiency are currently avail-
 
T
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Partial destruction of the adrenal cortex
 
Preexisting or previously undiagnosed asymptomatic diseases 
of the adrenal glands 
Autoimmune adrenalitis
Tuberculosis
Metastases
Acute partial destruction of the adrenal glands
Hemorrhage
Massive retroperitoneal bleeding
Thrombocytopenia
Anticoagulant therapy
Bacterial (meningococcemia), viral, or fungal infections
Previously unknown hypothalamic–pituitary disease resulting 
in undiagnosed secondary hypothalamic–pituitary–
adrenal insufficiency
Cytokine-mediated inhibition of corticotropin release during
septic shock?
 
47
 
Drug-related factors
 
Previously unknown corticosteroid therapy
Medroxyprogesterone, megestrol acetate
Increased metabolism of cortisol: phenytoin, phenobarbi-
tal, rifampin
Changes in cortisol synthesis: ketoconazole, etomidate,
aminoglutethimide, metyrapone, mitotane, trilostane
Interference with corticotropin action: suramin
Peripheral glucocorticoid-receptor blockade: mifepristone
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Figure 2.
 
 Effect of Anesthesia with Thiopental, Pancuronium, and Fentanyl (Control, Five Patients) and with Etomidate (Seven Pa-
tients) in Patients Undergoing Peroral Endoscopy and Microlaryngeal (Laser) Surgery of the Larynx.
The course of surgery and anesthesia (hour 0) and the outcome (up to 24 hours) were similar in both groups of patients, with no
subjective reports of symptoms and no differences in blood pressure. Note the inhibition of 11
 
b
 
-hydroxylation of the adrenal cortex
by etomidate, as evidenced by increased serum corticotropin and 11-deoxycortisol concentrations and lowered serum cortisol con-
centrations. Adapted from de Jong et al.
 
52
 
 with the permission of the publisher. To convert values for cortisol to nanomoles per
liter, multiply by 27.6; to convert values for deoxycortisol to nanomoles per liter, multiply by 28.9; to convert values for corticotropin
to picomoles per liter, multiply by 0.22.
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able. This diagnosis should be suspected, however,
when administration of hydrocortisone to severely ill
patients is followed by a period of diminished or no
need for vasopressor drugs.
 
CORTICOSTEROID THERAPY 
FOR CRITICAL ILLNESS
 
The value of high-dose corticosteroid therapy in
critically ill patients with an intact hypothalamic–
pituitary–adrenal axis is controversial. Most clinical
studies have been carried out in patients with sepsis,
often complicated by shock and multiorgan failure.
 
59
 
In two meta-analyses of the effect of corticosteroids
in patients with sepsis or septic shock,
 
60,61
 
 only 9 of
49 and 10 of 124 studies were considered of suffi-
cient methodologic quality to be included. Overall,
there was no beneficial effect of corticosteroids on
survival in patients with sepsis or septic shock.
 
60,61
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However, some circumstances and conditions in
which corticosteroid administration might have been
beneficial should be mentioned.
First, in some studies, administration of corticoster-
oids was beneficial only during the first few hours
after the onset of shock.
 
59
 
 The meta-analyses did not
address this aspect of the therapy because of lack of
information in the published trials about the time
of administration of corticosteroids. Nonetheless, de-
lays in administering corticosteroids could explain in
part the lack of benefit of corticosteroid therapy with
respect to outcome in patients with septic shock.
Second, in the two clinical trials with the best
methodologic-quality scores,
 
59,62
 
 patients with gram-
negative sepsis responded better to corticosteroid
treatment than did patients with other infections.
However, the slight advantage for the patients with
gram-negative sepsis was outweighed by a higher mor-
tality among the corticosteroid-treated patients with
sepsis that was caused by gram-positive organisms.
It is therefore possible that very early initiation of
treatment or even prophylactic therapy with cortico-
steroids in patients at risk for gram-negative infec-
tions might be effective in reducing the generalized
inflammatory response to those infections. Corti-
costeroids were also beneficial in randomized trials
in patients with bacterial meningitis,
 
63
 
 typhoid fe-
ver,
 
64
 
 acute spinal cord injury,
 
65
 
 
 
Pneumocystis carinii
 
pneumonia,
 
66
 
 and the adult respiratory distress syn-
drome.
 
67
 
Another shortcoming of the meta-analyses of stud-
ies of corticosteroids in patients with sepsis or septic
shock is the lack of information about patients with
underlying adrenocortical disease or relative adreno-
cortical insufficiency. Such patients benefit from cor-
ticosteroid treatment, but they are lost in the overall
analysis. Genetically based variations among normal
subjects in the threshold level of corticosteroid re-
sponses to stress could also affect the subjects’ surviv-
al when given corticosteroid therapy.
 
68,69
 
CORTICOSTEROID THERAPY IN PATIENTS 
WITH KNOWN ADRENAL DYSFUNCTION
 
Hypothalamic–pituitary–adrenal activation during
surgery and severe illness is even more complicated in
patients receiving corticosteroid therapy than in pa-
tients presumed to have previously normal adrenal
function. Patients receiving corticosteroid therapy
can be divided into two categories. One category
consists of patients with chronic autoimmune or
inflammatory diseases (such as asthma, ulcerative
colitis, rheumatoid arthritis, or skin disease) who are
being treated or have recently been treated with
high doses of corticosteroids. The second category
consists of patients receiving cortisol-replacement
therapy because of hypothalamic–pituitary–adrenal
hypofunction, whether of the hypothalamus (for ex-
ample, from previous irradiation), the pituitary (for
example, from adenomas), or the adrenals (for ex-
ample, from Addison’s disease).
 
Patients with Chronic Autoimmune or Inflammatory 
Diseases Treated with Corticosteroids
 
The duration of corticosteroid therapy, the high-
est dose, and the total cumulative dose have long
been considered important predictors of the sup-
pression of hypothalamic–pituitary–adrenal func-
tion.
 
70-74 However, high-dose corticosteroid therapy
and prolonged treatment do not invariably correlate
with the degree and duration of hypothalamic–pitu-
itary–adrenal suppression,72,73,75,76 and the time to
recovery after discontinuation of corticosteroid ther-
apy is highly variable. It can be as short as two to
five days76 or as long as nine months to one year.70,71
Therefore, it is hard to predict, on the basis of the
history of corticosteroid therapy, which patient will
have hypothalamic–pituitary–adrenal deficiency when
therapy is discontinued, even if the patient was tak-
ing a single daily dose or alternate-day doses.77,78
An important question is how well a test of hypo-
thalamic–pituitary–adrenal function predicts the re-
sponses of the cardiovascular system and of other sys-
tems to acute stress in a patient who has been treated
with corticosteroids. In an early study of several tests
(insulin-induced hypoglycemia, metyrapone, lysine
vasopressin, and corticotropin) and the subsequent
response to surgery in a group of corticosteroid-
treated patients,73,79 more patients had subnormal se-
rum cortisol responses to insulin and metyrapone
than to the other tests, but the best indicator of the
maximal serum cortisol concentration during surgery
was the peak serum cortisol concentration after the
administration of corticotropin.73,79,80
The most important measure of the value of any
test of hypothalamic–pituitary–adrenal function, how-
ever, is its ability to predict the clinical response of a
patient to the stress of surgery or acute illness. When
blood pressure during and after surgery is taken as
TABLE 2. SYMPTOMS AND SIGNS THAT RAISE THE 
SUSPICION OF HYPOADRENALISM IN CRITICALLY 
ILL PATIENTS.
Unexplained circulatory instability
Discrepancy between the anticipated severity of the disease 
and the present state of the patient, including nausea, 
vomiting, orthostatic hypotension, dehydration, abdom-
inal or flank pain (indicating acute adrenal hemorrhage), 
fatigue, and weight loss
High fever without apparent cause (negative cultures), not 
responding to antibiotic therapy
Unexplained mental changes: apathy or depression without a 
specific psychiatric disturbance
Vitiligo, altered pigmentation, loss of axillary or pubic hair, 
hypothyroidism, hypogonadism
Hypoglycemia, hyponatremia, hyperkalemia, neutropenia, 
eosinophilia
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the end point, neither basal nor corticotropin-stim-
ulated serum cortisol concentrations predict changes
in blood pressure in corticosteroid-treated patients
undergoing surgical stress without corticosteroid
supplementation.40,73,79
A number of case histories and more extensive
studies of corticosteroid-treated patients5,9-11,25,40,81-83
describe the catastrophic effects of hypocortisolism
during surgery and the dramatic beneficial effects of
corticosteroid therapy. In retrospect, however, many
confounding factors were present that make the in-
terpretation of these reports difficult. These factors
include interfering diseases, complications of surgery
or anesthesia, the use of drugs acting directly or in-
directly on adrenal function (Table 1), and the devel-
opment of the corticosteroid-withdrawal syndrome
in patients who suddenly stop long-term therapy with
high-dose corticosteroids,84 with symptoms and signs
similar to those of acute adrenal insufficiency (anorex-
ia, nausea, vomiting, weight loss, and depression).
Recent studies indicate that the daily rate of cor-
tisol production in normal subjects is lower than
previously thought (5.7 mg [15.7 mmol] per square
meter of body-surface area per day), as opposed to
12 to 15 mg (33 to 41 mmol) per square meter per
day.85 This lower rate of cortisol production corre-
sponds to about 10 to 12 mg of oral hydrocortisone
equivalent per square meter per day, because of in-
complete bioavailability resulting from first-pass he-
patic metabolism of oral hydrocortisone. In adults
the adrenal glands produce about 50 mg (138
mmol) of cortisol per 24 hours during minor surgi-
cal procedures and 75 to 150 mg (207 to 414
mmol) per 24 hours during major surgery40; cortisol
secretion in the first 24 hours after surgery seldom
exceeds 200 to 300 mg (552 to 828 mmol),9,40 sug-
gesting that in critically ill patients those are the
maximal doses of hydrocortisone that should be ad-
ministered, preferably as a continuous intravenous
infusion. The reasons for withholding higher doses
include the catabolic effects of high doses on muscle
and wound healing, the anti-insulin effects on glu-
cose metabolism, and the antiinflammatory effects
that may allow infections to worsen.9
In several recent studies of corticosteroid-treated
patients undergoing surgery while receiving their
previous doses, no patient had any intraoperative or
postoperative hypotension or other problems of any
kind.86-88 Studies in adrenalectomized monkeys also
support the concept that a replacement dose of hy-
drocortisone is enough to maintain normal cardiac
contractility and vascular tone during the stress of a
short, uncomplicated surgical procedure.18 However,
the doses of hydrocortisone given to these monkeys
during surgery might have been rather high (32 mg
[88 mmol] per square meter per day).
Larger doses of corticosteroids can blunt the en-
dogenous hypothalamic–pituitary–adrenal response
to surgery but are not associated with any clinical or
metabolic abnormalities. For example, the serum
cortisol concentrations during exploratory neck sur-
gery were lower in patients given 30 mg of predni-
sone for 10 days preoperatively than in untreated pa-
tients (Fig. 3), but none had any intraoperative or
postoperative problems.89
These results have led to the suggestion that for
elective surgery and most acute illnesses, continua-
tion of the current dose of corticosteroids suffices to
maintain cardiovascular function.86-88 However, if the
operation or acute illness is complicated or prolonged,
especially in the presence of the factors listed in Ta-
ble 1, higher doses of corticosteroids should be ad-
ministered, by doubling or tripling the current oral
dose or by giving hydrocortisone intravenously at a
dose of 100 to 150 mg daily.
The approach of increasing the dose of cortico-
steroids only in patients with complications or pro-
longed illness, however, has practical risks. Although
Figure 3. Effect of Anesthesia and Neck Exploration on Mean
(SE) Serum Cortisol Concentrations in Seven Control Patients
with a Thyroid Nodule and Six Patients with Primary Hyper-
parathyroidism Treated for 10 Days with 30 mg of Prednisone
Daily up to 3 Days before Operation.
During identical routine anesthesia and a similar surgical pro-
cedure, as well as during the subsequent 24 hours, there were
no differences in subjective reports of symptoms or blood
pressure between the two groups. Adapted from Janssens89
with the permission of the publisher. To convert values for cor-
tisol to nanomoles per liter, multiply by 27.6.
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most patients treated with 5 to 15 mg of prednisone
daily, for example, may respond normally, even to se-
vere stress,9,86,87 some may not, and if supplemental
corticosteroid is not given, physicians must remain
alert to the possibility of unexpected complications
for which additional corticosteroid might be benefi-
cial. Overtreatment for a day or two is unlikely to
cause any harm.
A consensus paper9 makes reasonable and clear
recommendations for the dose and duration of cor-
ticosteroid supplementation according to both the
previous dose and the severity of the surgical stress
and illness. For minor stress, a total dose of 25 mg
is recommended; for moderate stress, 50 to 75 mg;
and for major stress, 100 to 150 mg of hydrocorti-
sone or its equivalent should be given for one to
three days.9 A special group of patients consists of
those who receive corticosteroids topically (by inha-
lation, intranasally, transdermally, or by enema). Hy-
pothalamic–pituitary–adrenal suppression is very rare
in these patients,5,40 and it seems safe to withhold ad-
ditional corticosteroid during minor or moderate sur-
gical procedures or illnesses in these patients, as long
as their clinical course is uncomplicated.
Patients with Previously Diagnosed Hypothalamic–
Pituitary–Adrenal Insufficiency
Few, if any, patients receiving hydrocortisone-
replacement therapy for corticotropin or cortisol de-
ficiency have an increase in serum cortisol concen-
trations during surgery, trauma, infections, or other
severe illnesses. All these patients should be given
supplemental corticosteroid therapy in the form of
100 to 150 mg of hydrocortisone by continuous in-
travenous infusion during any severe illness or sur-
gery. Patients who travel frequently should wear a
bracelet with multilingual information concerning
their corticosteroid dependence.
CONCLUSIONS
During critical illness, the hypothalamic–pituitary–
adrenal axis is activated, as demonstrated by increased
serum corticotropin and cortisol concentrations. In
most patients with adrenal insufficiency, determi-
nation of the response of the serum cortisol con-
centration to corticotropin is helpful in making the
diagnosis. However, occult relative adrenal insuffi-
ciency, defined as a state in which corticosteroid ad-
ministration diminishes or eliminates the require-
ment for vasopressor drugs, rather than as a state
in which hypothalamic–pituitary–adrenal function is
clearly abnormal, may occur in some critically ill pa-
tients. Patients receiving treatment with cortico-
steroids for chronic autoimmune or inflammatory
diseases need less additional corticosteroid during
severe illness and perioperatively than those receiv-
ing replacement therapy for hypothalamic–pituitary–
adrenal insufficiency.
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